Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MYGN
stocks logo

MYGN

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
200.51M
-0.83%
-0.054
+443.9%
202.30M
-4.35%
-0.008
-116.02%
Estimates Revision
The market is revising Downward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by -3.74% over the past three months. During the same period, the stock price has changed by -22.01%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.74%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-108.37%
In Past 3 Month
Stock Price
Go Down
down Image
-22.01%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.10 USD with a low forecast of 4.00 USD and a high forecast of 18.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
2 Sell
Hold
up Image0
Current: 5.670
sliders
Low
4.00
Averages
8.10
High
18.00
up Image0
Current: 5.670
sliders
Low
4.00
Averages
8.10
High
18.00
Scotiabank
Outperform -> Sector Perform
downgrade
$20 -> $6
2025-05-21
Reason
Scotiabank
Price Target
$20 -> $6
2025-05-21
downgrade
Outperform -> Sector Perform
Reason
As previously reported, Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a price target of $6, down from $20. While the firm continues to believe there is opportunity for Myriad to execute against its Oncology and Women's Health business ambitions over the next several years, 2025 is likely to be "a transitional year," the analyst tells investors in a research note. The firm would like to see tangible and consistent progress and also waits for a potential strategy reset under the new CEO before turning more positive on shares, the analyst added.
BofA
Underperform
downgrade
$9 -> $4
2025-05-20
Reason
BofA
Price Target
$9 -> $4
2025-05-20
downgrade
Underperform
Reason
BofA lowered the firm's price target on Myriad Genetics to $4 from $9 and keeps an Underperform rating on the shares following what the firm says was "another disappointing quarter," headlined by a $35M reduction to sales guidance. Myriad has continued to experience headwinds and "the company has not managed to turn the page," says the analyst, who updated estimates accounting for continued headwinds and revised guidance.
Scotiabank
Outperform -> Sector Perform
downgrade
$6
2025-05-20
Reason
Scotiabank
Price Target
$6
2025-05-20
downgrade
Outperform -> Sector Perform
Reason
Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a $6 price target.
Morgan Stanley
Tejas Savant
Equal Weight
downgrade
$16 -> $7
2025-05-19
Reason
Morgan Stanley
Tejas Savant
Price Target
$16 -> $7
2025-05-19
downgrade
Equal Weight
Reason
Morgan Stanley analyst Tejas Savant lowered the firm's price target on Myriad Genetics to $7 from $16 and keeps an Equal Weight rating on the shares. A "disappointing" Q1 miss was driven by softness in GeneSight and hereditary cancer tests in the unaffected population, says the analyst, who adds that while the pipeline "holds promise," it "remains a show-me story at this time."
Piper Sandler
Overweight -> NULL
downgrade
$9
2025-05-15
Reason
Piper Sandler
Price Target
$9
2025-05-15
downgrade
Overweight -> NULL
Reason
Piper Sandler lowered the firm's price target on Myriad Genetics to $9 from $12.50 following quarterly results. The firm keeps an Overweight rating on the shares.
Goldman Sachs
Matthew Sykes
Strong Buy
Maintains
$18 → $14
2025-04-17
Reason
Goldman Sachs
Matthew Sykes
Price Target
$18 → $14
2025-04-17
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Myriad Genetics Inc (MYGN.O) is 81.22, compared to its 5-year average forward P/E of -32.65. For a more detailed relative valuation and DCF analysis to assess Myriad Genetics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-32.65
Current PE
81.22
Overvalued PE
400.51
Undervalued PE
-465.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
37.67
Current EV/EBITDA
15.36
Overvalued EV/EBITDA
123.39
Undervalued EV/EBITDA
-48.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
2.34
Current PS
0.44
Overvalued PS
3.17
Undervalued PS
1.52

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MYGN News & Events

Events Timeline

(ET)
2025-08-05
17:08:31
Myriad Genetics backs FY25 adjusted EPS view (2c)-2c, consensus 1c
select
2025-08-05
17:06:28
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c)
select
2025-07-31 (ET)
2025-07-31
08:35:22
Myriad Genetics announces $200M credit facility
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
08-06Newsfilter
PinnedMyriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

  • Earnings Conference Call: Myriad Genetics held its Q2 2025 earnings conference call on August 5, 2025, where key executives discussed financial results and future outlook.

  • Participants: The call featured various company leaders including CEO Samraat S. Raha and CFO Scott J. Leffler, along with analysts from multiple research divisions who participated in the Q&A session.

Preview
9.5
08-06Benzinga
PinnedMyriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance

  • Strong Quarterly Performance: Myriad Genetics Inc. reported second-quarter revenue of $213.1 million, surpassing analyst expectations, and achieved a non-GAAP profit of $0.05 per share, leading to a 35.7% surge in stock price after-hours.

  • Increased Revenue Guidance and Strategic Moves: The company raised its full-year revenue guidance and secured a $200 million term loan facility with OrbiMed, while focusing on an updated strategy for growth in the Cancer Care Continuum.

Preview
2.0
08-06Benzinga
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday

  • U.S. Stock Market Performance: U.S. stocks saw a mostly positive trend, with the Dow Jones index increasing by approximately 0.1% on Wednesday, driven by strong earnings reports from several companies.

  • Notable Stock Gains: Shopify's shares surged 21.5% after exceeding sales expectations, while other companies like Astera Labs and Myriad Genetics also reported significant gains following better-than-expected quarterly results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Myriad Genetics Inc (MYGN) stock price today?

The current price of MYGN is 5.67 USD — it has increased 46.51 % in the last trading day.

arrow icon

What is Myriad Genetics Inc (MYGN)'s business?

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

arrow icon

What is the price predicton of MYGN Stock?

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.10 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Myriad Genetics Inc (MYGN)'s revenue for the last quarter?

Myriad Genetics Inc revenue for the last quarter amounts to 195.90M USD, decreased -3.12 % YoY.

arrow icon

What is Myriad Genetics Inc (MYGN)'s earnings per share (EPS) for the last quarter?

Myriad Genetics Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Myriad Genetics Inc (MYGN)'s fundamentals?

The market is revising Downward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by -3.74% over the past three months. During the same period, the stock price has changed by -22.01%.
arrow icon

How many employees does Myriad Genetics Inc (MYGN). have?

Myriad Genetics Inc (MYGN) has 2700 emplpoyees as of August 07 2025.

arrow icon

What is Myriad Genetics Inc (MYGN) market cap?

Today MYGN has the market capitalization of 527.88M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free